Montgomery Community Media

Novavax, a vaccine development company headquartered in Gaithersburg, announced Thursday that it entered into a Memorandum of Understanding (MOU) with an international vaccine organization to provide more than 1 billion total doses of Novavax’s COVID-19 vaccine candidate, according to a statement from the company. Novavax will work with Gavi, the Vaccine Alliance to provide 1.1 […]

Novavax, a vaccine development company headquartered in Gaithersburg, has initiated Phase 3 for its COVID-19 vaccine candidate.  It is the fifth candidate to reach Phase 3 in the U.S., after Pfizer, Moderna, AstraZeneca and Janssen. Novavax is looking for volunteers to participate in vaccine trials, particularly those who are part of at-risk populations like Hispanics, […]

Gaithersburg biotechnology company Novavax announced Monday that it has reached an agreement in principle to give Canada up to 76 million doses of Novavax’s COVID-19 vaccine.  In a statement the company said the vaccine is in multiple Phase 2 clinical trials right now. Novavax expects to finalize an agreement that would begin supplying the doses […]

A vaccine development company headquartered in Gaithersburg is starting clinical trials for a potential COVID-19 vaccine.  Novavax will administer the trials for vaccine candidate NVX‑CoV2373 in two phases, a statement from the company says. Phase 1 will test 131 people in Australia for immune response and safety. Results are expected in July. “Administering our vaccine […]

Human testing of a second investigational Ebola vaccine candidate is underway at the National Institutes of Health’s Clinical Center in Bethesda, according to the NIH website. Researchers at the National Institute of Allergy and Infectious Diseases are conducting the early phase trial to evaluate the vaccine, called VSV-ZEBOV, for safety and its ability to generate […]